Massively Parallel Sequencing Reveals an Accumulation of De Novo Mutations and an Activating Mutation of LPAR1 in a Patient with Metastatic Neuroblastoma

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Wei, Jun S ^a   Johansson, Peter ^a   Chen, Li ^a   Song, Young K ^a   Tolman, Catherine ^a   Li, Samuel ^a   Hurd, Laura ^a   Patidar, Rajesh ^a   Wen, Xinyu ^a,b   Badgett, Thomas C ^a   Cheuk, Adam T C ^a   Marshall, Jean Claude ^a   Steeg, Patricia S ^a   Vaqué Díez, José P ^c   Yu, Yanlin ^a   Gutkind, J Silvio ^c   Khan, Javed ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

^c NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; G PROTEIN COUPLED RECEPTOR; PROTEIN LPAR1; RHO FACTOR; TRANSCRIPTION FACTOR GATA 2; TRANSCRIPTOME; TRYPTOPHAN; UNCLASSIFIED DRUG;

ADRENAL TUMOR; ADULT; ANIMAL CELL; ARTICLE; ATRX GENE; AUTOPSY; BONE MARROW BIOPSY; CANCER PATIENT; DISEASE COURSE; FEMALE; GATA2 GENE; GENE DELETION; GENE EXPRESSION; GENETIC ANALYSIS; HEMIZYGOSITY; HUMAN; LIVER METASTASIS; LPAR1 GENE; MOUSE; MUTATIONAL ANALYSIS; NEUROBLASTOMA; NONHUMAN; NUCLEOTIDE SEQUENCE; NUFIP1 GENE; PROTEIN EXPRESSION; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; SOMATIC MUTATION; TUMOR GENE;

ANIMALS; FEMALE; GATA2 TRANSCRIPTION FACTOR; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MICE; MUTAGENESIS, SITE-DIRECTED; MUTATION; NEUROBLASTOMA; NIH 3T3 CELLS; NUCLEAR PROTEINS; RECEPTORS, LYSOPHOSPHATIDIC ACID; RNA-BINDING PROTEINS; YOUNG ADULT;

EID: 84885729752     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0077731     Document Type: Article

References (67)

1. Goodman M, Gurney JG, Smith MA, Olshan AF, (1999) Cancer Incidence and Survival Among Children and Adolescents. United States SEER Program. pp. pp. 1975-1995, Sympathetic nervous system tumors. http://seer.cancer.gov/publications/childhood/sympathetic.pdf. Accessed 2013 September 16.
2. Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, et al. (2010) Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 363: 1324-1334. doi:10.1056/NEJMoa0911123. PubMed: 20879881.
3. Esiashvili N, Goodman M, Ward K, Marcus RB Jr., Johnstone PA, (2007) Neuroblastoma in adults: Incidence and survival analysis based on SEER data. Pediatr Blood Cancer 49: 41-46. doi:10.1002/pbc.20859. PubMed: 16628557.
4. Castel V, Villamón E, Cañete A, Navarro S, Ruiz A, et al. (2010) Neuroblastoma in adolescents: genetic and clinical characterisation. Clin Transl Oncol 12: 49-54. doi:10.1007/s12094-010-0466-z. PubMed: 20080471.
5. Podda MG, Luksch R, Polastri D, Gandola L, Piva L, et al. (2010) Neuroblastoma in patients over 12 years old: a 20-year experience at the Istituto Nazionale Tumori of Milan. Tumori 96: 684-689. PubMed: 21302612.
6. Schwab M, Alitalo K, Klempnauer KH, Varmus HE, Bishop JM, et al. (1983) Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour. Nature 305: 245-248. doi:10.1038/305245a0. PubMed: 6888561.
7. Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM, (1984) Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 224: 1121-1124. doi:10.1126/science.6719137. PubMed: 6719137.
8. Seeger RC, Brodeur GM, Sather H, Dalton A, Siegel SE, et al. (1985) Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 313: 1111-1116. doi:10.1056/NEJM198510313131802. PubMed: 4047115.
9. Attiyeh EF, London WB, Mossé YP, Wang Q, Winter C, et al. (2005) Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med 353: 2243-2253. doi:10.1056/NEJMoa052399. PubMed: 16306521.
10. Chen Y, Takita J, Choi YL, Kato M, Ohira M, et al. (2008) Oncogenic mutations of ALK kinase in neuroblastoma. Nature 455: 971-974. doi:10.1038/nature07399. PubMed: 18923524.
11. George RE, Sanda T, Hanna M, Fröhling S, Luther W 2nd, et al. (2008) Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 455: 975-978. doi:10.1038/nature07397. PubMed: 18923525.
12. Mossé YP, Laudenslager M, Longo L, Cole KA, Wood A, et al. (2008) Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 455: 930-935. doi:10.1038/nature07261. PubMed: 18724359.
13. Janoueix-Lerosey I, Lequin D, Brugières L, Ribeiro A, de Pontual L, et al. (2008) Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 455: 967-970. doi:10.1038/nature07398. PubMed: 18923523.
14. Cheung NK, Zhang J, Lu C, Parker M, Bahrami A, et al. (2012) Association of age at diagnosis and genetic mutations in patients with neuroblastoma. JAMA 307: 1062-1071. doi:10.1001/jama.2012.228. PubMed: 22416102.
15. Molenaar JJ, Koster J, Zwijnenburg DA, van Sluis P, Valentijn LJ, et al. (2012) Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes. Nature 483: 589-593. doi:10.1038/nature10910. PubMed: 22367537.
16. Sausen M, Leary RJ, Jones S, Wu J, Reynolds CP, et al. (2012) Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma. Nat Genet 45: 12-17. doi:10.1038/ng.2493. PubMed: 23202128.
17. Pugh TJ, Morozova O, Attiyeh EF, Asgharzadeh S, Wei JS, et al. (2013) The genetic landscape of high-risk neuroblastoma. Nat Genet, 45: 279-84. PubMed: 23334666.
18. Banerji S, Cibulskis K, Rangel-Escareno C, Brown KK, Carter SL, et al. (2012) Sequence analysis of mutations and translocations across breast cancer subtypes. Nature 486: 405-409. doi:10.1038/nature11154. PubMed: 22722202.
19. The Cancer Genome Atlas Research Network (2012) Comprehensive molecular characterization of human colon and rectal cancer. Nature 487: 330-337. doi:10.1038/nature11252. PubMed: 22810696.
20. Berger MF, Hodis E, Heffernan TP, Deribe YL, Lawrence MS, et al. (2012) Melanoma genome sequencing reveals frequent PREX2 mutations. Nature 485: 502-506. PubMed: 22622578.
21. Drmanac R, Sparks AB, Callow MJ, Halpern AL, Burns NL, et al. (2010) Human genome sequencing using unchained base reads on self-assembling DNA nanoarrays. Science 327: 78-81. doi:10.1126/science.1181498. PubMed: 19892942.
22. Wang K, Li M, Hakonarson H, (2010) ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res 38: e164. doi:10.1093/nar/gkq603. PubMed: 20601685.
23. Wei JS, Greer BT, Westermann F, Steinberg SM, Son CG, et al. (2004) Prediction of clinical outcome using gene expression profiling and artificial neural networks for patients with neuroblastoma. Cancer Res 64: 6883-6891. doi:10.1158/0008-5472.CAN-04-0695. PubMed: 15466177.
24. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, et al. (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 102: 15545-15550. doi:10.1073/pnas.0506580102. PubMed: 16199517.
25. Horak CE, Lee JH, Elkahloun AG, Boissan M, Dumont S, et al. (2007) Nm23-H1 suppresses tumor cell motility by down-regulating the lysophosphatidic acid receptor EDG2. Cancer Res 67: 7238-7246. doi:10.1158/0008-5472.CAN-07-0962. PubMed: 17671192.
26. George RE, Attiyeh EF, Li S, Moreau LA, Neuberg D, et al. (2007) Genome-wide analysis of neuroblastomas using high-density single nucleotide polymorphism arrays. PLOS ONE 2: e255. doi:10.1371/journal.pone.0000255. PubMed: 17327916.
27. Stephens PJ, Greenman CD, Fu B, Yang F, Bignell GR, et al. (2011) Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell 144: 27-40. doi:10.1016/j.cell.2010.11.055. PubMed: 21215367.
28. Hecht JH, Weiner JA, Post SR, Chun J, (1996) Ventricular zone gene-1 (vzg-1) encodes a lysophosphatidic acid receptor expressed in neurogenic regions of the developing cerebral cortex. J Cell Biol 135: 1071-1083. doi:10.1083/jcb.135.4.1071. PubMed: 8922387.
29. Van Leeuwen FN, Olivo C, Grivell S, Giepmans BN, Collard JG, et al. (2003) Rac activation by lysophosphatidic acid LPA1 receptors through the guanine nucleotide exchange factor Tiam1. J Biol Chem 278: 400-406. PubMed: 12393875.
30. Choi JW, Herr DR, Noguchi K, Yung YC, Lee CW, et al. (2010) LPA receptors: subtypes and biological actions. Annu Rev Pharmacol Toxicol 50: 157-186. doi:10.1146/annurev.pharmtox.010909.105753. PubMed: 20055701.
31. Kumar P, Henikoff S, Ng PC, (2009) Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc 4: 1073-1081. doi:10.1038/nprot.2009.86. PubMed: 19561590.
32. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, et al. (2010) A method and server for predicting damaging missense mutations. Nat Methods 7: 248-249. doi:10.1038/nmeth0410-248. PubMed: 20354512.
33. Mili S, Moissoglu K, Macara IG, (2008) Genome-wide screen reveals APC-associated RNAs enriched in cell protrusions. Nature 453: 115-119. doi:10.1038/nature06888. PubMed: 18451862.
34. Berenjeno IM, Núñez F, Bustelo XR, (2007) Transcriptomal profiling of the cellular transformation induced by Rho subfamily GTPases. Oncogene 26: 4295-4305. doi:10.1038/sj.onc.1210194. PubMed: 17213802.
35. Kranenburg O, Poland M, van Horck FP, Drechsel D, Hall A, et al. (1999) Activation of RhoA by lysophosphatidic acid and Galpha12/13 subunits in neuronal cells: induction of neurite retraction. Mol Cell Biol 10: 1851-1857. doi:10.1091/mbc.10.6.1851. PubMed: 10359601.
36. Chen M, Towers LN, O'Connor KL, (2007) LPA2 (EDG4) mediates Rho-dependent chemotaxis with lower efficacy than LPA1 (EDG2) in breast carcinoma cells. Am J Physiol Cell Physiol 292: C1927-C1933. PubMed: 17496233.
37. Yachida S, Jones S, Bozic I, Antal T, Leary R, et al. (2010) Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467: 1114-1117. doi:10.1038/nature09515. PubMed: 20981102.
38. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, et al. (2012) Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366: 883-892. doi:10.1056/NEJMoa1113205. PubMed: 22397650.
39. Heaphy CM, de Wilde RF, Jiao Y, Klein AP, Edil BH, et al. (2011) Altered telomeres in tumors with ATRX and DAXX mutations. Science 333: 425. doi:10.1126/science.1207313. PubMed: 21719641.
40. Schwartzentruber J, Korshunov A, Liu XY, Jones DT, Pfaff E, et al. (2012) Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 482: 226-231. doi:10.1038/nature10833. PubMed: 22286061.
41. Lovejoy CA, Li W, Reisenweber S, Thongthip S, Bruno J, et al. (2012) Loss of ATRX, Genome Instability, and an Altered DNA Damage Response Are Hallmarks of the Alternative Lengthening of Telomeres Pathway. PLOS Genet 8: e1002772. PubMed: 22829774.
42. Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, et al. (2002) Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 346: 645-652. doi:10.1056/NEJMoa011573. PubMed: 11870241.
43. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, et al. (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362: 2380-2388. doi:10.1056/NEJMoa0909530. PubMed: 20573926.
44. Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, et al. (2012) Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 367: 107-114. doi:10.1056/NEJMoa1203421. PubMed: 22663011.
45. Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, et al. (2008) Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455: 1069-1075. doi:10.1038/nature07423. PubMed: 18948947.
46. Jones DT, Jäger N, Kool M, Zichner T, Hutter B, et al. (2012) Dissecting the genomic complexity underlying medulloblastoma. Nature 488: 100-105. doi:10.1038/nature11284. PubMed: 22832583.
47. Shah SP, Köbel M, Senz J, Morin RD, Clarke BA, et al. (2009) Mutation of FOXL2 in granulosa-cell tumors of the ovary. N Engl J Med 360: 2719-2729. doi:10.1056/NEJMoa0902542. PubMed: 19516027.
48. Cabart P, Chew HK, Murphy S, (2004) BRCA1 cooperates with NUFIP and P-TEFb to activate transcription by RNA polymerase II. Oncogene 23: 5316-5329. doi:10.1038/sj.onc.1207684. PubMed: 15107825.
49. Deshpande GP, Hayles J, Hoe KL, Kim DU, Park HO, et al. (2009) Screening a genome-wide S. pombe deletion library identifies novel genes and pathways involved in genome stability maintenance. DNA Repair (Amst) 8: 672-679. doi:10.1016/j.dnarep.2009.01.016. PubMed: 19264558.
50. Mitter D, Ullmann R, Muradyan A, Klein-Hitpass L, Kanber D, et al. (2011) Genotype-phenotype correlations in patients with retinoblastoma and interstitial 13q deletions. Eur J Hum Genet 19: 947-958. doi:10.1038/ejhg.2011.58. PubMed: 21505449.
51. Caselli R, Speciale C, Pescucci C, Uliana V, Sampieri K, et al. (2007) Retinoblastoma and mental retardation microdeletion syndrome: clinical characterization and molecular dissection using array CGH. J Hum Genet 52: 535-542. doi:10.1007/s10038-007-0151-4. PubMed: 17502991.
52. Mladenov E, Anachkova B, Tsaneva I, (2006) Sub-nuclear localization of Rad51 in response to DNA damage. Genes Cells 11: 513-524. doi:10.1111/j.1365-2443.2006.00958.x. PubMed: 16629903.
53. Willett RT, Greene LA, (2011) Gata2 is required for migration and differentiation of retinorecipient neurons in the superior colliculus. J Neurosci 31: 4444-4455. doi:10.1523/JNEUROSCI.4616-10.2011. PubMed: 21430145.
54. Tsai FY, Keller G, Kuo FC, Weiss M, Chen J, et al. (1994) An early haematopoietic defect in mice lacking the transcription factor GATA-2. Nature 371: 221-226. doi:10.1038/371221a0. PubMed: 8078582.
55. Nardelli J, Thiesson D, Fujiwara Y, Tsai FY, Orkin SH, (1999) Expression and genetic interaction of transcription factors GATA-2 and GATA-3 during development of the mouse central nervous system. Dev Biol 210: 305-321. doi:10.1006/dbio.1999.9278. PubMed: 10357893.
56. Chen QR, Vansant G, Oades K, Pickering M, Wei JS, et al. (2007) Diagnosis of the small round blue cell tumors using multiplex polymerase chain reaction. J Mol Diagn 9: 80-88. doi:10.2353/jmoldx.2007.060111. PubMed: 17251339.
57. Khan J, Wei JS, Ringnér M, Saal LH, Ladanyi M, et al. (2001) Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks. Nat Med 7: 673-679. doi:10.1038/89044. PubMed: 11385503.
58. Hahn CN, Chong CE, Carmichael CL, Wilkins EJ, Brautigan PJ, et al. (2011) Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia. Nat Genet 43: 1012-1017. doi:10.1038/ng.913. PubMed: 21892162.
59. Ostergaard P, Simpson MA, Connell FC, Steward CG, Brice G, et al. (2011) Mutations in GATA2 cause primary lymphedema associated with a predisposition to acute myeloid leukemia (Emberger syndrome). Nat Genet 43: 929-931. doi:10.1038/ng.923. PubMed: 21892158.
60. Obo Y, Yamada T, Furukawa M, Hotta M, Honoki K, et al. (2009) Frequent mutations of lysophosphatidic acid receptor-1 gene in rat liver tumors. Mutat Res 660: 47-50. doi:10.1016/j.mrfmmm.2008.10.005. PubMed: 19000703.
61. Yamada T, Obo Y, Furukawa M, Hotta M, Yamasaki A, et al. (2009) Mutations of lysophosphatidic acid receptor-1 gene during progression of lung tumors in rats. Biochem Biophys Res Commun 378: 424-427. doi:10.1016/j.bbrc.2008.11.044. PubMed: 19026987.
62. Park SY, Jeong KJ, Panupinthu N, Yu S, Lee J, et al. (2011) Lysophosphatidic acid augments human hepatocellular carcinoma cell invasion through LPA1 receptor and MMP-9 expression. Oncogene 30: 1351-1359. doi:10.1038/onc.2010.517. PubMed: 21102517.
63. Boucharaba A, Serre CM, Grès S, Saulnier-Blache JS, Bordet JC, et al. (2004) Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer. J Clin Invest 114: 1714-1725. doi:10.1172/JCI200422123. PubMed: 15599396.
64. Shida D, Kitayama J, Yamaguchi H, Okaji Y, Tsuno NH, et al. (2003) Lysophosphatidic acid (LPA) enhances the metastatic potential of human colon carcinoma DLD1 cells through LPA1. Cancer Res 63: 1706-1711. PubMed: 12670925.
65. Hama K, Aoki J, Fukaya M, Kishi Y, Sakai T, et al. (2004) Lysophosphatidic acid and autotaxin stimulate cell motility of neoplastic and non-neoplastic cells through LPA1. J Biol Chem 279: 17634-17639. doi:10.1074/jbc.M313927200. PubMed: 14744855.
66. Yamada T, Sato K, Komachi M, Malchinkhuu E, Tobo M, et al. (2004) Lysophosphatidic acid (LPA) in malignant ascites stimulates motility of human pancreatic cancer cells through LPA1. J Biol Chem 279: 6595-6605. PubMed: 14660630.
67. Olshen AB, Venkatraman ES, Lucito R, Wigler M, (2004) Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics 5: 557-572. doi:10.1093/biostatistics/kxh008. PubMed: 15475419.